Production (Stage)
Entrada Therapeutics, Inc.
TRDA
$7.59
-$0.26-3.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -1,633.95% | 108.06% | -125.50% | 134.21% | 346.19% |
| Total Depreciation and Amortization | -4.64% | 5.87% | 2.97% | -2.57% | 26.90% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 70.95% | 33.15% | -30.24% | 39.21% | -7.93% |
| Change in Net Operating Assets | 28.03% | -180.24% | 30.60% | 64.24% | -1,848.90% |
| Cash from Operations | -21.84% | -30.24% | -160.92% | 256.09% | -535.91% |
| Capital Expenditure | -80.16% | 0.63% | 38.91% | -24.82% | 14.14% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -89.02% | 165.62% | -252.61% | -186.48% | 34.80% |
| Cash from Investing | -91.04% | 164.35% | -240.10% | -193.25% | 37.31% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -75.04% | -- | -- | 49,107.28% | -70.14% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -75.04% | 12,845.45% | -100.01% | 49,107.28% | -70.14% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -244.09% | 121.61% | -191.77% | 13,906.83% | -94.69% |